PMM2-CDG
Clinical trials for PMM2-CDG explained in plain language.
Never miss a new study
Get alerted when new PMM2-CDG trials appear
Sign up with your email to follow new studies for PMM2-CDG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for rare disease: new drug shows promise in Long-Term study
Disease control ENROLLING_BY_INVITATIONThis study is for people with PMM2-CDG, a rare genetic disorder, who have already taken the experimental drug GLM101 in a previous trial. The goal is to see if GLM101 is safe and effective over a longer period. Participants will receive weekly infusions of GLM101 at the same dose…
Matched conditions: PMM2-CDG
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental drug GLM101 targets rare PMM2-CDG in pivotal trial
Disease control OngoingThis study tests a drug called GLM101 for people with PMM2-CDG, a rare inherited disease that affects movement and coordination. About 50 children and adults will receive weekly infusions of either GLM101 or a placebo for 24 weeks, followed by an open-label phase where everyone g…
Matched conditions: PMM2-CDG
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC